Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $23.80

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been given a consensus rating of “Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $23.80.

Several brokerages recently weighed in on LXEO. HC Wainwright raised their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners cut their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently modified their holdings of LXEO. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. purchased a new position in Lexeo Therapeutics in the 4th quarter valued at $46,000. BNP Paribas Financial Markets grew its position in Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics in the 3rd quarter valued at $67,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Lexeo Therapeutics in the 4th quarter valued at $69,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Trading Up 6.6 %

Shares of LXEO opened at $4.50 on Tuesday. The firm has a 50-day moving average price of $6.04 and a 200 day moving average price of $8.30. The firm has a market capitalization of $148.82 million, a P/E ratio of -1.42 and a beta of 2.99. Lexeo Therapeutics has a 12-month low of $3.84 and a 12-month high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.